

# BD Launches Next Generation Microbiology Solution for Liquid and Non-liquid Sample Processing

## **BD Kiestra™ InoquIA system is available in Europe (CE marked)**

**FRANKLIN LAKES, N.J., July 28, 2020** – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced availability in Europe (CE marked) of the new BD Kiestra™ InoquIA system powered by BD Synapsys™ informatics solution.

The BD Kiestra™ InoquIA, which is available as a standalone instrument for microbiology labs, is a high throughput solution that offers enhanced workflow flexibility allowing the user to seamlessly switch between two modes to process liquid and non-liquid samples, enabling on demand processing of urgent samples and continuous loading and unloading of samples and plates during operation, minimizing interruptions to workflow. The system uses unique rolling-bead technology to generate more discrete colonies than traditional manual loop-based streaking.

“Sample processing has historically been manual, error-prone, and labor-intensive,” said Cecilia Soriano, vice president and general manager of Microbiology at BD. “The BD Kiestra™ InoquIA allows the user to prioritize urgent samples immediately for on-demand processing minimizing workflow interruption. The BD Kiestra™ InoquIA also reduces the need for subculture, which may shorten the time for microbial identification and antibiotic susceptibility testing, allowing earlier result reporting.”

BD Synapsys™ informatics solution is an advanced, secure and scalable platform that provides connectivity for several BD diagnostic instruments, rules-based workflow and on-demand actionable insights to help laboratories impact their performance. BD Kiestra™ InoquIA, powered by BD Synapsys™ informatics solution, supports complete traceability of plates through automatically generated barcodes. Several workflow enhancements—offline inoculation, simplified batch ordering processes, and custom culture protocols can be easily viewed via custom reports in the BD Synapsys™ informatics solution.

BD continues to invest in automation and innovation for the microbiology laboratory. For more information on BD Kiestra™ lab automation solutions, please visit <https://www.bd.com/en-us/offerings/capabilities/lab-automation>.

## **About the BD Kiestra™ laboratory automation solutions**

BD Kiestra™ lab automation solutions provide total lab automation for the clinical microbiology laboratory. These solutions are designed to enhance laboratory operations, increase financial efficiencies and advance laboratory operations. BD Kiestra™ lab automation offerings include scalable and modular microbiology workflow automation solutions, ranging from standalone units to fully automated track-based automation systems for mid- and high-volume labs.

## **About BD Synapsys™ informatics solutions**

BD Synapsys™ informatics solution enables laboratories to address challenges and improve laboratory outcomes. It enables labs to enhance performance using microbiology informatics through a single, advanced platform with an intuitive, personalized user interface. BD Synapsys™ informatics solution offers integrated workflow and on-demand insights to help expedite decision making, enhance productivity and help support compliance. [Learn more](#) about BD Synapsys™ informatics solution.

## **About BD**

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.

For more information on BD, please visit [bd.com](https://www.bd.com)

---

Additional assets available online:  [Photos \(1\)](#)

<https://news.bd.com/2020-07-28-BD-Launches-Next-Generation-Microbiology-Solution-for-Liquid-and-Non-liquid-Sample-Processing>